Aminopeptidase inhibition as a targeted treatment strategy in myeloma

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 762-770

  Moore, Hannah E ^a   Davenport, Emma L ^a   Smith, Emma M ^a   Muralikrishnan, Srikanth ^a   Dunlop, Alan S ^a   Walker, Brian A ^a   Krige, David ^b   Drummond, Alan H ^b   Hooftman, Leon ^b   Morgan, Gareth J ^a   Davies, Faith E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Chroma Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMINOPEPTIDASE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE; CHR 2797; DEXAMETHASONE; MELPHALAN; PROTEASOME; PROTEIN MCL 1; PROTEIN NOXA; UBIQUITIN; UNCLASSIFIED DRUG; VASCULOTROPIN; 2 (2 (HYDROXY(HYDROXYCARBAMOYL)METHYL) 4 METHYLPENTANOYLAMINO) 2 PHENYLETHANOIC ACID CYCLOPENTYL ESTER; 2-(2-(HYDROXY(HYDROXYCARBAMOYL)METHYL)-4-METHYLPENTANOYLAMINO)-2-PHENYLETHANOIC ACID CYCLOPENTYL ESTER; DRUG DERIVATIVE; GLYCINE; HYDROXAMIC ACID; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; AUTOPHAGY; BONE MARROW CELL; CANCER INHIBITION; CATALYSIS; CELL ADHESION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROLYSIS; MICROENVIRONMENT; MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN METABOLISM; PROTEIN TARGETING; STROMA CELL; UPREGULATION; CELL CYCLE; DRUG ANTAGONISM; ENZYMOLOGY; IMMUNOBLOTTING; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; TUMOR CELL CULTURE;

AMINOPEPTIDASES; APOPTOSIS; BONE MARROW CELLS; CASPASES; CELL CYCLE; CELL PROLIFERATION; GLYCINE; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; MULTIPLE MYELOMA; STROMAL CELLS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66449121341     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0735     Document Type: Article

References (24)

1. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609-2617 (Pubitemid 36741588)
2. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-16647 (Pubitemid 34967682)
3. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-14379 (Pubitemid 35257679)
4. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-1534 (Pubitemid 36182530)
5. Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial- mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005;65:3828-3836 (Pubitemid 40616363)
6. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-4916 (Pubitemid 43882644)
7. Davenport EL, Moore HE, Dunlop AS, et al. Heat shock protein inhibition is associated with activation of the unfolded protein response (UPR) pathway in myeloma plasma cells. Blood 2007;110:2641-2649 (Pubitemid 47523188)
8. Moerschell RP, Hoskawa Y, Tsunasawa S, Sherman F. The specificities of yeast methionine aminopeptidase and acetylation of amino-terminal methionine in vivo. J Biol Chem 1990;265:19638-19643
9. Botbol V, Scornik OA. Measurement of instant rates of protein degradation in the livers of intact mice by the accumulation of bestatin-induced peptides. J Biol Chem 1991;266:2151-2157 (Pubitemid 21909042)
10. Constam DB, Tobler AR, Rensing-Ehl A, Kemler I, Hersh LB, Fontana A. Puromycin-sensitive aminopeptidase. Sequence analysis, expression, and functional characterization. J Biol Chem 1995;270:26931-26939
11. Scott L, Lamb J, Smith S, Wheatley DN. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 2000;83:800-810
12. Wheatley DN, Scott L, Lamb J, Smith S. Single amino acid (arginine) restriction: growth and death of cultured HeLa and human diploid fibroblasts. Cell Physiol Biochem 2000;10:37-55. (Pubitemid 30219714)
13. Ichinose Y, Genka K, Koike T, et al. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell carcinoma. J Natl Cancer Inst 2003;95:605-610 (Pubitemid 36553507)
14. Ota K, Uzuka Y. Clinical trials of bestatin for leukemia and solid tumors. Biotherapy 1992;4:205-214
15. Krige D, Needham LA, Bawden LJ, et al. CHR-2797 an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukaemia cells. Cancer Res 2008;68:6669-6679
16. Walker BA, Leone PE, Jenner MW, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006;108:1733-1743 (Pubitemid 44316144)
17. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681 (Pubitemid 44403686)
18. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15: 1950-1961 (Pubitemid 33115003)
19. Kilberg MS, Barbosa-Tessmann IP. Genomic sequences necessary for transcriptional activation by amino acid deprivation of mammalian cells. J Nutr 2002;132:1801-1804 (Pubitemid 34742859)
20. Seibenhener ML, Geetha T, Wooten MW. Sequestosome 1/p62- more than just a scaffold. FEBS Lett 2007;581:175-179 (Pubitemid 46096472)
21. Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin- 6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 2003;278:5794-5801 (Pubitemid 36800825)
22. Podar K, Shringarpure R, Tai YT, et al. Calveolin-1 is required for the vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 2004;64:7500-7506 (Pubitemid 39372094)
23. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. Noxa upregulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007;67:5418-5424 (Pubitemid 46997282)
24. Davies F, Ossenkoppele G, Zachee P, et al. A phase I study of CHR- 2797, an orally active aminopeptidase inhibitor in elderly and/or treatment refractory patients with acute myeloid leukemia or multiple myeloma. Blood 2007;110:abstract 443.